Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Dual-functional Ni and Co oxide-doped carbon nanocomposite: an effective catalyst for electrochemical water splitting and CO<sub>2</sub> utilization.

RSC advances·2026
Same author

Novel mercapto conjugates of oleanolic acid as potential antifungal agents.

Archives of microbiology·2026
Same author

Polypharmacology in multi-drug-resistant tuberculosis: current scenario and future promise.

RSC medicinal chemistry·2026
Same author

Corrigendum to "Inhibition of mycobacteria proliferation in macrophages by diaryl ether derivatives of Dehydrozingerone compound and repurposed drugs (Rebamipide, Sofalcone) via NF-κB pathway inhibition" [Tuberculosis, 155(2025), 102706].

Tuberculosis (Edinburgh, Scotland)·2025
Same author

Fabrication of starch-based hydrogels as drug controlled release carriers: Characterization, anti-bacterial, and cytotoxicity assessment.

International journal of biological macromolecules·2025
Same author

Efficient magnetic sorbent for extracting bisphenol A from aqueous samples.

RSC advances·2025

Related Experiment Video

Updated: Jun 27, 2026

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel Film
04:09

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel Film

Published on: December 13, 2024

Alginate-based sustained release drug delivery systems for tuberculosis.

Zahoor Ahmad1, G K Khuller

  • 1Postgraduate Institute of Medical Education & Research, Department of Biochemistry, 160 012, Chandigarh, India.

Expert Opinion on Drug Delivery
|December 2, 2008
PubMed
Summary

Alginate drug delivery systems offer controlled release of tuberculosis medications, improving patient compliance and combating multi-drug resistance. This natural polymer enhances treatment efficacy for chronic infectious diseases.

More Related Videos

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Disposable Dosators Intended for Dry Powder Delivery to Mice
04:59

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

Related Experiment Videos

Last Updated: Jun 27, 2026

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel Film
04:09

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel Film

Published on: December 13, 2024

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Disposable Dosators Intended for Dry Powder Delivery to Mice
04:59

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Pharmacology

Background:

  • Drug delivery systems offer therapeutic advantages like controlled release and reduced toxicity, crucial for chronic diseases such as tuberculosis.
  • Patient non-compliance in tuberculosis treatment leads to treatment failure and the development of multi-drug resistant tuberculosis.
  • Alginate, a natural, biodegradable, and non-toxic polymer, is suitable for drug encapsulation due to its compatibility with various molecules and sustained release properties.

Purpose of the Study:

  • To explore the potential of alginate as a drug delivery system for tuberculosis treatment.
  • To investigate alginate's ability to co-encapsulate multiple antitubercular drugs.
  • To assess the controlled release profile of antitubercular drugs from alginate formulations.

Main Methods:

  • Literature review on alginate properties and drug delivery applications.
  • Analysis of studies documenting alginate's controlled release of various drugs.
  • Focus on alginate's capacity for co-encapsulation of multiple antitubercular agents.

Main Results:

  • Alginate demonstrates sustained release potential for a wide range of drugs.
  • The polymer exhibits compatibility with both hydrophobic and hydrophilic drug molecules.
  • Alginate can co-encapsulate multiple antitubercular drugs, offering a controlled release profile.

Conclusions:

  • Alginate-based drug delivery systems show significant promise for tuberculosis management.
  • The controlled release of multiple antitubercular drugs from alginate can enhance patient compliance.
  • This approach has the potential to improve treatment outcomes and mitigate the emergence of drug resistance in tuberculosis.